The resolution of the Expert Council on Interstitial Lung Diseases in Systemic Scleroderma (Moscow, October 14, 2019)
https://doi.org/10.14412/1996-7012-2020-1-125-128
Abstract
The conclusion of the Expert Council presents the results of discussing the diagnosis and therapy of interstitial lung diseases in systemic scleroderma. The reason for this discussion was the emergence of new data on the use of nintedanib in this category of patients.
About the Authors
S. N. Avdeev
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991
L. P. Ananyeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
E. V. Zhilyaev
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
2/1, Barrikadnaya St., Build. 1, Moscow 125993
Russian Federation
2/1, Barrikadnaya St., Build. 1, Moscow 125993
E. V. Zonova
Novosibirsk State Medical University, Ministry of Health of Russia
Russian Federation
52, Krasnyi Prospect, Novosibirsk 630091
Russian Federation
52, Krasnyi Prospect, Novosibirsk 630091
A. A. Klimenko
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
1, Ostrovityanov St., Moscow 117997
Russian Federation
1, Ostrovityanov St., Moscow 117997
O. A. Koneva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
V.A. Nasonova Research Institute of Rheumatology
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology;
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
V.A. Nasonova Research Institute of Rheumatology;
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
E. S. Pershina
N.I. Pirogov City Clinical Hospital One, Moscow Healthcare Department
Russian Federation
8, Leninsky Prospect, Moscow 119049
Russian Federation
8, Leninsky Prospect, Moscow 119049
A. A. Stremoukhov
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
S. A. Terpigorev
Faculty for Postgraduate Training of Physicians, M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
61/2, Shchepkin St., Build. 1, Moscow 129110
Russian Federation
61/2, Shchepkin St., Build. 1, Moscow 129110
I. E. Tyurin
Novosibirsk State Medical University, Ministry of Health of Russia
Russian Federation
52, Krasnyi Prospect, Novosibirsk 630091
Russian Federation
52, Krasnyi Prospect, Novosibirsk 630091
N. A. Shostak
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
1, Ostrovityanov St., Moscow 117997
Russian Federation
1, Ostrovityanov St., Moscow 117997
References
1. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747-55. doi: 10.1136/annrheumdis-2013-204424
2. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2007;66: 754-63. doi: 10.1136/ard.2006.062901
3. Jaeger VK, Wirz EG, Allanore Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One. 2016;11(10):e0163894. doi: 10.1371/journal.pone.0163894
4. Frantz C, Avouac J, Distler O, et al. Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey. Semin Arthritis Rheum. 2016;46:115-23. doi: 10.1016/j.semarthrit.2016.02.005
5. Fischer A, Zimovetz E, Ling C, et al. Humanistic and cost burden of systemic sclerosis: a review of the literature. Autoimmun Rev. 2017;16:1147-54. doi: 10.1016/j.autrev.2017.09.010
6. Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76: 1897-905. doi: 10.1136/annrheumdis-2017- 211448
7. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354: 2655-66. doi: 10.1056/NEJMoa055120
8. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomized controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4:708-19. doi: 10.1016/S2213-2600(16)30152-7
9. Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015; 45:1434-45. doi: 10.1183/09031936.00174914
10. Чучалин АГ, Авдеев СН, Айсанов ЗР и др. Диагностика и лечение идиопатического легочного фиброза. Федеральные клинические рекомендации. Пульмонология. 2016;26(4):399-419. [Chuchalin AG, Avdeev SN, Aysanov ZR, et al. Diagnosis and treatment of idiopathic pulmonary fibrosis. Federal clinical guidelines. Pul'monologiya. 2016;26(4):399-419 (In Russ.)].
11. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011; 365:1079-87. doi: 10.1056/NEJMoa1103690
12. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370:2071-82. doi: 10.1056/NEJMoa1402584
13. Kikuchi K, Kadono T, Ihn H, et al. Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-beta 1. J Invest Dermatol. 1995; 105:128-32. doi: 10.1111/1523-1747.ep12313452
14. Hsu E, Shi H, Jordan RM, et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 2011;63:783-94. doi: 10.1002/art.30159
15. Lam AP, Flozak AS, Russell S, et al. Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am J Respir Cell Mol Biol. 2011;45:915-22. doi: 10.1165/rcmb.2010-0113OC
16. Huang J, Maier C, Zhang Y, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017;76: 1941-8. doi: 10.1136/annrheumdis-2016- 210823
17. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518-28. doi: 10.1056/NEJM oa1903076
18. Flaherty KR, Wells AU, Vincent Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019; 381:1718-27. doi: 10.1056/NEJMoa1908681
Review
For citations:
Avdeev SN, Ananyeva LP, Zhilyaev EV, Zonova EV, Klimenko AA, Koneva OA, Lila AM, Pershina ES, Stremoukhov AA, Terpigorev SA, Tyurin IE, Shostak NA. The resolution of the Expert Council on Interstitial Lung Diseases in Systemic Scleroderma (Moscow, October 14, 2019). Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2020;14(1):125-128. (In Russ.) https://doi.org/10.14412/1996-7012-2020-1-125-128
Views:
1022
Email this article 